EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

What are the optimal pharmacokinetic/pharmacodynamic targets for β-lactamase inhibitors? A systematic review

Getnet M Assefa, Jason A Roberts iD, Solomon A Mohammed, Fekade B Sime iD

Journal of Antimicrobial Chemotherapy · 02.05.2024 · 79 (5) · 946-958

DOI: 10.1093/jac/dkae058 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 09.03.2024. Verfasst von Getnet M Assefa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, Anti-Bacterial Agents, Microbial Sensitivity Tests. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pharmacokinetic/pharmacodynamic (PK/PD) indices are widely used for the selection of optimum antibiotic doses. For β-lactam antibiotics, fT>MIC, best relates antibiotic exposure to efficacy and is widely used to guide the dosing of β-lactam/β-lactamase inhibitor (BLI) combinations, often without considering any PK/PD exposure requirements for BLIs.

Objectives

This systematic review aimed to describe the PK/PD exposure requirements of BLIs for optimal microbiological efficacy when used in combination with β-lactam antibiotics.

Methods

Literature was searched online through PubMed, Embase, Web of Science, Scopus and Cochrane Library databases up to 5 June 2023. Studies that report the PK/PD index and threshold concentration of BLIs approved for clinical use were included. Narrative data synthesis was carried out to assimilate the available evidence.

Results

Twenty-three studies were included. The PK/PD index that described the efficacy of BLIs was fT>CT for tazobactam, avibactam and clavulanic acid and fAUC0–24/MIC for relebactam and vaborbactam. The optimal magnitude of the PK/PD index is variable for each BLI based on the companion β-lactam antibiotics, type of bacteria and β-lactamase enzyme gene transcription levels.

Conclusions

The PK/PD index that describes the efficacy of BLIs and the exposure measure required for their efficacy is variable among inhibitors; as a result, it is difficult to make clear inference on what the optimum index is. Further PK/PD profiling of BLI, using preclinical infection models that simulate the anticipated mode(s) of clinical use, is warranted to streamline the exposure targets for use in the optimization of dosing regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-Lactamase InhibitorsAnti-Bacterial AgentsMicrobial Sensitivity TestsHumansbeta-Lactamsbeta-Lactamases

Substanzen

beta-Lactamase InhibitorsAnti-Bacterial Agentsbeta-Lactamsbeta-Lactamases

Autor:innen und Institutionen

  • Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
  • Department of Pharmacy, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia.
  • Pharmacy Department, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
  • Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
  • Herston Infectious Disease Institute (HeIDI), Metro North Health, Brisbane, QLD, Australia.
  • Division of Anaesthesiology Critical Care Emerging and Pain Medicine, Nimes University Hospital, University of Montpellier, Nimes, France.

ORCID-Profile: Jason A Roberts, Fekade B Sime

Zitieren

APA

Assefa, G. M., Roberts, J. A., Mohammed, S. A., & Sime, F. B. (2024). What are the optimal pharmacokinetic/pharmacodynamic targets for β-lactamase inhibitors? A systematic review. Journal of Antimicrobial Chemotherapy, 79(5), 946-958. https://doi.org/10.1093/jac/dkae058

Vancouver

Assefa GM, Roberts JA, Mohammed SA, Sime FB. What are the optimal pharmacokinetic/pharmacodynamic targets for β-lactamase inhibitors? A systematic review. Journal of Antimicrobial Chemotherapy. 2024;79(5):946-958. doi:10.1093/jac/dkae058

BibTeX
@article{Assefa2024,
  author = {Assefa, Getnet M and Roberts, Jason A and Mohammed, Solomon A and Sime, Fekade B},
  title = {What are the optimal pharmacokinetic/pharmacodynamic targets for β-lactamase inhibitors? A systematic review},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  volume = {79},
  number = {5},
  pages = {946--958},
  doi = {10.1093/jac/dkae058}
}
Kostenlos starten →